ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Circulating Levels of Angiotensinogen, Sex Hormones, and Hormone Therapy-The Multi-Ethnic Study of Atherosclerosis (MESA).
Karita C F Lidani, Patrick J Trainor, Robert Buscaglia, Kristoff Foster, Sophia Jaramillo, Kirolos Michael, Alexander P Landry, Erin D Michos, Pamela Ouyang, Erin S Morgan and 2 more
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Karita C F LidaniDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0003-4675-8733
Patrick J TrainorDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Robert BuscagliaDepartment of Mathematics and Statistics, Northern Arizona University, Arizona, USA.
Kristoff FosterDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sophia JaramilloDepartment of Chemistry and Biochemistry, New Mexico State University, Las Cruces, New Mexico, USA.
Kirolos MichaelMeharry Medical College, Nashville, Tennessee, USA.
Alexander P LandryDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Erin D MichosDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-5547-5084
Pamela OuyangInstitute for Clinical and Translational Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Erin S MorganIonis Pharmaceuticals, Carlsbad, California, USA.
Sotirios TsimikasIonis Pharmaceuticals, Carlsbad, California, USA.
Andrew P DeFilippisDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Funding
NM-INBRE Sequencing and Bioinformatics CoreP20GM103451 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI Charlotte C. Gard · 2012 to 2026
$61.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00002 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN J · 2020 to 2025
$3.4M
Integrated proteomic and metabolomics analysis of thrombotic myocardial infarctionSC1GM139730 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI TRAINOR, PATRICK J · 2021 to 2024
$888k
Institutional Development Award (IDeA) from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health P20GM103451Ionis Pharmaceuticals, IncNCATS NIH HHS UL1-TR-000040NCATS NIH HHS UL1-TR-001079NCATS NIH HHS UL1-TR-001420NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003INIGMS NIH HHS P20 GM103451NIGMS NIH HHS SC1 GM139730Research Enhancement Award to PT from NIGMS SC1GM139730the National Heart, Lung, and Blood Institute N01-HC-95159the National Heart, Lung, and Blood Institute N01-HC-95160the National Heart, Lung, and Blood Institute N01-HC-95161the National Heart, Lung, and Blood Institute N01-HC-95162the National Heart, Lung, and Blood Institute N01-HC-95163the National Heart, Lung, and Blood Institute N01-HC-95164the National Heart, Lung, and Blood Institute N01-HC-95165the National Heart, Lung, and Blood Institute N01-HC-95166the National Heart, Lung, and Blood Institute N01-HC-95167the National Heart, Lung, and Blood Institute N01-HC-95168the National Heart, Lung, and Blood Institute N01-HC-95169
6 · The paper itself
Abstract
Angiotensinogen, the unique precursor of all angiotensin hormones of the renin-angiotensin-aldosterone system (RAAS), is now a potential target in a novel pharmacological approach to hypertension. Investigating the factors that influence angiotensinogen levels, including sex hormones, may have important therapeutic implications. Plasma angiotensinogen and sex hormones levels were measured in 5171 Multi-Ethnic Study of Atherosclerosis (MESA) participants. Linear models were employed to determine the associations of angiotensinogen with sex hormones. Angiotensinogen levels were significantly higher in postmenopausal women receiving hormone therapy (HT, n = 760) compared to women not receiving HT (n = 1675) and in men (n = 2736). A positive association was present between angiotensinogen and estrogen levels that differed in magnitude between sexes and by HT status among postmenopausal women (women on HT: r = 0.44, p < 0.0001; women not on HT: r = 0.09, p = 0.0002; and men: r = 0.07, p = 0.0003). The type of HT formulation (estrogen or estrogen/progesterone) and its duration of use did not significantly affect angiotensinogen levels. This study suggests a significant role of sex, estrogen, and HT in the pathophysiology of angiotensinogen, which is important given the development and testing of angiotensinogen-targeting therapeutics.
Indexed as
AngiotensinogenAtherosclerosisGonadal Steroid HormonesAgedAged, 80 and overEstrogen Replacement TherapyEstrogensEthnicityFemaleHumansHypertensionMaleMiddle AgedPostmenopauseRenin-Angiotensin SystemSex FactorsAngiotensinogenEstrogensGonadal Steroid Hormonesangiotensinogenestradiolhormone therapyrenin‐angiotensin‐aldosterone system
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Circulating Levels of Angiotensinogen, Sex Hormones, and Hormone Therapy-The Multi-Ethnic Study of Atherosclerosis (MESA). · full record | OpenQuestion